In a groundbreaking initiative, the US Department of Defense (DoD) is set to explore the use of MDMA-assisted therapy as a treatment for active-duty soldiers suffering from post-traumatic stress disorder (PTSD). Commencing next year, this research programme will involve 186 service members and aims to provide therapeutic relief from the psychological burdens associated with military service.
Pioneering Research on Psychedelic Treatment
The decision to incorporate MDMA therapy into military healthcare comes as part of a broader strategy to address the mental health crisis within the armed forces. The research is being closely monitored by Sean O’Keefe, the deputy under secretary of war for personnel and readiness, reflecting a significant shift in how the military approaches mental health treatment.
Training for a new cohort of therapists from the DoD and Veterans Affairs (VA) is set to begin imminently, paving the way for the enrolment of soldiers into the programme. This move is underpinned by the hope that MDMA, known for its euphoric effects, can help soldiers process traumatic experiences, ultimately allowing them to serve longer and transition more effectively to civilian life.
“Helping people process trauma, whoever they are, is probably better than not,” remarked Rick Doblin, founding president of the Multidisciplinary Association for Psychedelic Studies (Maps). His organisation has been pivotal in pushing for the approval of MDMA-assisted therapy, which is now on the verge of federal endorsement.
Legislative Support and Historical Context
The funding for these studies was secured through the National Defence Authorization Act, signed by former President Joe Biden in December 2023. This act included provisions championed by Congressman Morgan Luttrell, a veteran and former Navy Seal, who stated, “Our men and women in uniform deserve every tool available to heal and stay in the fight. This is just the beginning.”
On 18 April, Luttrell joined former President Donald Trump as he signed an executive order aimed at expediting research into psychedelics for veterans. “The suicide epidemic among veterans is a national tragedy,” Trump noted, highlighting the critical need for innovative treatment methods in light of the staggering suicide rates among service members.
Historically, the US military has employed various substances to treat PTSD, including barbiturates during World War II. However, these methods proved ineffective in providing lasting relief. MDMA and other psychedelics like psilocybin are now being recognised for their potential to deliver more profound mental health benefits.
Ethical Considerations and Future Implications
Despite the promising prospects of psychedelic therapy, experts have raised ethical concerns about the potential for soldiers to be re-traumatised after treatment. Dennis McKenna, an ethnobotanist, cautioned against the cynical use of such therapies to enhance combat readiness, arguing that it would be inherently cruel to restore individuals to health only to send them back into conflict.
“There’s a risk that individuals may relapse if they return to a high-stress environment shortly after treatment,” Doblin acknowledged. As the US military prepares to implement these studies, it is essential to consider the long-term welfare of the soldiers involved.
The situation in Ukraine serves as a contemporary parallel, where Maps has trained therapists to administer MDMA-assisted therapy to soldiers grappling with untreated PTSD amidst ongoing conflict. While MDMA therapy remains illegal in Ukraine, many soldiers have already engaged in legal treatments involving ketamine, aiming to cope with the psychological toll of warfare.
The Path Ahead
The upcoming trials will be the first of their kind to systematically investigate the effects of psychedelics on active-duty soldiers. With the potential to reshape military mental health practices, the studies at the Walter Reed National Military Medical Center and Emory University could signal a new era in therapeutic approaches to PTSD.
As the military gears up for this unprecedented research, the implications of psychedelic therapy extend beyond the battlefield, raising important questions about emotional resilience and the psychological readiness of service members.
Why it Matters
This initiative represents a significant transformation in the military’s approach to mental health, potentially setting a precedent for how PTSD is treated in both military and civilian populations. As the military continues to grapple with the consequences of conflict on mental health, the integration of innovative therapeutic techniques like MDMA-assisted therapy could pave the way for a more compassionate and effective healthcare model for those who serve. The outcome of these studies may not only alter the lives of soldiers but could also influence broader societal attitudes towards the use of psychedelics in mental health treatment.
